CytoDyn Inc. announced it is working with Chiral Pharma Corp. in the Philippines to register Vyrologix under a licensed physician’s request for Compassionate Special Permit (CSP) to treat COVID-19 patients with leronlimab for a fee. Last night, the CytoDyn team presented the results from various studies (primarily from U.S. eIND patients) of leronlimab as a potential therapeutic for COVID-19 patients to several Philippine regulators, hospital executives and physicians. Drs. Seethamraju and Agresti discussed their patient experiences with leronlimab for critical COVID-19 patients under eIND. References were also made to several published papers by Drs. Otto Yang and Nicholas Agresti, among others, for the treatment of COVID-19 patients with leronlimab. CytoDyn appointed Chiral Pharma, a subsidiary of New Marketlink Pharmaceutical Corporation (NMPC), to register Vyrologix™ for potential approval from the Food and Drug Administration in the Philippines to treat COVID-19 patients.